Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Public ClinicalTrials.gov record NCT04811040. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and zinlirvimab (formerly GS-2872) in combination with the HIV capsid inhibitor lenacapavir (LEN).
Study identification
- NCT ID
- NCT04811040
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Interventions
- Oral Lenacapavir Drug
- Subcutaneous Lenacapavir Drug
- Teropavimab Drug
- Zinlirvimab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 8, 2021 (Actual)
- Primary completion
- Jun 9, 2022 (Actual)
- Completion
- Oct 26, 2023 (Actual)
- Last update posted
- Jan 27, 2025
2021 – 2023
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ruane Clinical Research Group Inc. | Los Angeles | California | 90036 | — |
| Mills Clinical Research | Los Angeles | California | 90069 | — |
| One Community Health | Sacramento | California | 95811 | — |
| UCSD AntViral Research Center (AVRC) | San Diego | California | 92103 | — |
| Yale University; School of Medicine; AIDS Program | New Haven | Connecticut | 06510 | — |
| Midway Immunology and Research Center | Ft. Pierce | Florida | 34982 | — |
| University of Miami Miller School of Medicine Schiff Center for Liver Disease | Miami | Florida | 33136 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Triple O Research Institute, P.A | West Palm Beach | Florida | 33407 | — |
| Mercer University, Department of Internal Medicine | Macon | Georgia | 31201 | — |
| Indiana CTSI Clinical Research Center | Indianapolis | Indiana | 46202 | — |
| National Institutes of Health/Clinical Center | Bethesda | Maryland | 20892 | — |
| Be Well Medical Center | Berkley | Michigan | 48072 | — |
| AXCES Research Group | Santa Fe | New Mexico | 87505 | — |
| Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center | New York | New York | 10029 | — |
| NC TraCS Institute-CTRC; University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| The Brody School of Medicine at East Carolina University, ECU Adult Specialty Care | Greenville | North Carolina | 27834 | — |
| Rosedale Health & Wellness | Huntersville | North Carolina | 28078 | — |
| Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| Central Texas Clinical Research | Austin | Texas | 78705 | — |
| The Crofoot Research, INC. | Houston | Texas | 77098 | — |
| Peter Shalit, M.D. | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04811040, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 27, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04811040 live on ClinicalTrials.gov.